Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
biocon
July 2021
January 2021
November 2020
April 2020
February 2020
January 2020
Mix and match vaccines, says Kiran Mazumdar-Shaw
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
Syngene’s winning formula
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
Hope floats for Covid-19 vaccine candidates in India
The DCGI has given the nod for two vaccines and phase 1 of the vaccination process is expected to begin soon. Zydus Cadila’s vaccine candidate has also been cleared for phase 3 trials.
Biocon’s biosimilar biz tops $4 bn in valuation
Abu Dhabi-based sovereign wealth fund ADQ has picked up 1.80% stake in Biocon Biologics for $75 million; The company already raised $255 million from global marquee investors last year.
Healthcare leaders shine in MPW 2020 list
Cipla’s Samina Hamied, Lupin’s Vinita Gupta biggest rank gainers from the sector.
‘Restart economy sooner than later’
India is likely to recover faster than the rest of the world from the economic turmoil caused by Covid-19, with new opportunities presenting themselves, says Biocon chairperson.
SC agrees to amend order making Covid-19 tests free
An earlier judgment by the apex court making Coronavirus tests free across the board had sparked concerns over the viability of the private sector’s participation in testing for the virus.
Shaw named EY Entrepreneur of the Year
The award recognises entrepreneurs who, with their disruptive ideas and passion for growth, are creating successful global enterprises.
True North invests ₹536 crore in Biocon arm
The private equity firm’s investment values Biocon Biologics at about $3 billion on a pre-money equity basis.
